Yellow fever vaccines and international travelers

References

• Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin. Infect. Dis.34(10), 1369–1378 (2002).
   PubMed Web of Science ®Google Scholar
• Monath TP. Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am. J. Trop. Med. Hyg.45, 1–43 (1991).
   PubMed Web of Science ®Google Scholar
• Robertson SE, Hull BP, Tomori O et al. Yellow fever: a decade of reemergence. JAMA276, 1157–1162 (1996).
   PubMed Web of Science ®Google Scholar
• Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In: Vaccines. Plotkin S, Orenstein W, Offit P (Eds). Elsevier, UK 959–1055 (2008).
   Google Scholar
• Powell JM. Bring Out Your Dead: the Great Plague of Yellow Fever in Philadelphia in 1793. University of Pennsylvania Press, PA, USA (1949).
   Google Scholar
• Bloom KJ. The Mississippi Valley’s Great Yellow Fever Epidemic of 1878. Louisiana State University Press, LA, USA (1993).
   Google Scholar
• Humphreys M. Yellow Fever and the South. Rutgers University Press, NJ, USA (1992).
   Google Scholar
• Carrigan JA. The Saffron Scourge: a History of Yellow Fever in Louisiana 1796–1905. University of Southwestern Louisiana, LA, USA (1994).
   Google Scholar
• Sanders EJ, Marfin AA, Tukei PM et al. First recorded outbreak of yellow fever in Kenya, 1992–1993. I. Epidemiologic investigations. Am. J. Trop. Med. Hyg.59, 644–649 (1998).
   PubMed Web of Science ®Google Scholar
• Wilson ME, Chen LH, Barnett ED. Yellow fever immunizations: indications and risks. Curr. Infect. Dis. Rep.6(1), 34–42 (2004).
   PubMedGoogle Scholar
• Barnett ED. Yellow fever: epidemiology and prevention. Clin. Infect. Dis.44(6), 850–856 (2007).
   PubMed Web of Science ®Google Scholar
• Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv. Virus Res.60, 343–395 (2003).
   PubMed Web of Science ®Google Scholar
• Nasisi A, Monath TP, DeCock K et al. Urban yellow fever epidemic in western Nigeria, 1987. Trans. R. Soc. Trop. Med. Hyg.83, 401–406 (1989).
   PubMedGoogle Scholar
• Rozenzweig EC, Babione RW, Wisseman CL Jr. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with17D strain yellow fever vaccine. Am. J. Trop. Med. Hyg.12, 230–235 (1963).
   PubMedGoogle Scholar
• Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody to yellow fever virus 30–35 years following immunization with 17D yellow fever vaccine: a study of World War II veterans in 1975–1976. Bull. World Health Organ.59, 895–900 (1981).
   PubMed Web of Science ®Google Scholar
• Groot H, Riberiro RB. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull. World Health Organ.27, 699–707 (1962).
   PubMed Web of Science ®Google Scholar
• Hepburn MJ, Kortepeter MG, Pittman PR et al. Neutralizing antibody response to booster vaccination with the 17D yellow fever vaccine. Vaccine24, 2843–2849 (2006).
   PubMed Web of Science ®Google Scholar
• Sweet BH, Wisseman CJ Jr, Kitaoka M. Immunological studies with group B arthropod-borne viruses. II. Effect of prior infection with Japanese encephalitis virus on the viremia in human subjects following administration of 17D yellow fever vaccine. Am. J. Trop. Med. Hyg.11, 652 (1962).
   Google Scholar
• Pond WL, Ehrenkranz JN, Danauskas JX, Carter MJ. Heterotypic serologic responses after yellow fever vaccination; detection of persons with past St. Louis encephalitis or dengue. J. Immunol.98, 673–682 (1967).
   PubMedGoogle Scholar
• Belmusto-Worn VE, Sanchez JL, McCarthy K et al. Randomized, double-blind, Phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am. J. Trop. Med. Hyg.72, 187–197 (2005).
   Google Scholar
• Hacker UT, Jelinek T, Erhardt S et al.In vivo synthesis of tumor necrosis factor-α in healthy humans after live yellow fever vaccination. J. Infect. Dis.177, 774–778 (1998).
   PubMed Web of Science ®Google Scholar
• Reinhardt B, Jaspert R, Niedrig M et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J. Med. Virol.56, 159–167 (1998).
   PubMed Web of Science ®Google Scholar
• Martins MA, Silva ML, Marciano AP et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin. Exp. Immunol.148, 90–100 (2007).
   PubMed Web of Science ®Google Scholar
• Martins MA, Silva ML, Eloi-Santos SM et al. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine26, 1173–1184 (2008).
   PubMed Web of Science ®Google Scholar
• Barban V, Girerd Y, Aguirre M et al. High stability of yellow fever 17D-204 vaccine: a 12-year retrospective analysis of large-scale production. Vaccine25, 2941–2950 (2007).
   PubMed Web of Science ®Google Scholar
• Vellozzi C, Mitchell T, Miller E et al. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996–2004. Am. J. Trop. Med. Hyg.75, 333–336 (2006).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Yellow fever vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.51(RR-17), 4–6 (2002)
   Google Scholar
• McMahon AW, Eidex RB, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine25, 1727–1734 (2007).
   PubMed Web of Science ®Google Scholar
• Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J. Med. Assoc. Thai.85, 131–134 (2002).
   PubMedGoogle Scholar
• Eidex RB, Hayes EB, Russell M. Yellow fever. In: Centers for Disease Control and Prevention. Health Information for International Travel (2008). US Department of Health and Human Services, Public Health Service, GA, USA (2007).
   Google Scholar
• Khromava AY, Eidex RB, Weld LH et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine23, 3256–3263 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination – United States, 2001–2002. MMWR Morb. Mortal. Wkly Rep.51, 989–993 (2002).
   PubMedGoogle Scholar
• Fernandes GC, Camacho LAB, Carvalho MS, Batista M, de Almeida SMR. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999–2005. Vaccine25, 3124–3128 (2007).
   PubMed Web of Science ®Google Scholar
• Bae H-G, Domingo C, Tenorio A et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J. Infect. Dis.197, 1577–1584 (2008).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996–2001. MMWR Morb. Mortal. Wkly Rep.50, 643–645 (2001).
   PubMedGoogle Scholar
• Engel AR, Vasconcelos PFC, McArthur MA, Barrett ADT. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine24, 2803–2809 (2006).
   PubMed Web of Science ®Google Scholar
• Martin M, Weld LH, Tsai TF et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg. Infect. Dis.7, 945–951 (2001).
   PubMed Web of Science ®Google Scholar
• Monath TP, Cetron MS, McCarthy K et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Human Vaccines1(5), e1–e8 (2005).
   PubMedGoogle Scholar
• Barwick RE. History of thymoma and yellow fever vaccination. Lancet364, 936 (2004).
   PubMed Web of Science ®Google Scholar
• Tsai T. Congenital arboviral infections: something new, something old. Pediatrics117, 936–939 (2006).
   PubMedGoogle Scholar
• Nishioka Sde A, Nunes-Araujo FR, Pires WP, Silva FA, Costa HL. Yellow fever vaccination during pregnancy and spontaneous abortion: a case–control study. Trop. Med. Int. Health3(1), 29–33 (1998).
   PubMedGoogle Scholar
• Suzano CE, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine24(9), 1421–1426 (2006).
   PubMed Web of Science ®Google Scholar
• Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans. R. Soc. Trop. Med. Hyg.87(3), 337–339 (1993).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Hill D, Freedman DO. Practical implications of the revised international vaccine certificate. Am. J. Trop. Med. Hyg.78(3), 359–360 (2008).
   PubMed Web of Science ®Google Scholar
• Hardiman M, Wilder-Smith A. The revised international health regulations and their relevance to travel medicine. J. Travel Med.14(3), 141–144 (2007).
   PubMedGoogle Scholar
• Guirakhoo F, Arroyo J, Pugachev KV et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever–dengue virus tetravalent vaccine. J. Virol.75(16), 7290–7304 (2001).
   PubMed Web of Science ®Google Scholar